Authors' objectives: Urothelial bladder cancer starts to develop in the bladder lining. In some cases the tumour spreads into the surrounding muscles or other parts of the body, which means that it cannot be cured by surgery. Most bladder cancers occur in people aged over 60 years. Almost one third of people diagnosed with bladder cancer will be diagnosed with disease that has spread outside of the bladder. Nivolumab is a new antibody drug for the treatment of bladder cancer and is delivered straight into the bloodstream via a drip. It may stimulate the immune system to attack cancer cells. A study underway at the moment is aiming to find out how well nivolumab works in people whose first treatment has failed and whose disease has spread. If nivolumab is licenced for use in the UK, it could be a new treatment option for patients with bladder cancer that may improve survival when current treatments have stopped working.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/nivolumab-opdivo-for-metastatic-or-unresectable-urothelial-bladder-cancer-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)